Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension

Quantifying the relationship between inhibition of VEGF receptor 2, drug-induced blood pressure elevation and hypertension

(2018) Teresa Collins et al.   BRITISH JOURNAL OF PHARMACOLOGY

Current and Emerging Therapies for First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma

(2018) Michael B. Atkins et al.   CANCER TREATMENT REVIEWS

Endothelin type B (ET B ) receptors: friend or foe in the pathogenesis of pre-eclampsia and future cardiovascular disease (CVD) risk?

(2018) Katrina M. Mirabito Colafella   CLINICAL SCIENCE

Vascular endothelial growth factor signaling in development and disease

(2018) Sinem Karaman et al.   DEVELOPMENT

Pazopanib-Induced Hypertension in Patients With Renal Cell Carcinoma Is Associated With Low Urine Excretion of NO MetabolitesNovelty and Significance

(2018) Anne Robdrup Tinning et al.   HYPERTENSION

Renin-Angiotensin-Aldosterone Profiles in Pregnant Women With Chronic HypertensionNovelty and Significance

(2018) Line Malha et al.   HYPERTENSION

VEGFR (Vascular Endothelial Growth Factor Receptor) Inhibition Induces Cardiovascular Damage via Redox-Sensitive ProcessesNovelty and Significance

(2018) Karla B. Neves et al.   HYPERTENSION

The role of distal tubule and collecting duct sodium reabsorption in sunitinib-induced hypertension

(2018) Jeannine Witte et al.   JOURNAL OF HYPERTENSION

Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events

(2018) Rhian M. Touyz et al.   Journal of the American Society of Hypertension

Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future

(2018) Mark A. Perazella et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer

(2018) Giandomenico Roviello et al.   Oncotarget

Sunitinib-induced blood pressure rise does not involve aldosterone

(2018) Jorie Versmissen et al.   JOURNAL OF HYPERTENSION

Pre-eclampsia is associated with altered expression of the renal sodium transporters NKCC2, NCC and ENaC in urinary extracellular vesicles

(2018) Chih-Chiang Hu et al.   PLoS One

Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib

(2017) Michiel C. Verboom et al.   EUROPEAN JOURNAL OF CANCER

Novel Mechanism for Buffering Dietary Salt in HumansNovelty and Significance

(2017) Viknesh Selvarajah et al.   HYPERTENSION

Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor–Associated Hypertension and Vascular Disease

(2017) Arvind K. Pandey et al.   HYPERTENSION

Angiogenic Markers Predict Pregnancy Complications and Prolongation in PreeclampsiaNovelty and Significance

(2017) Langeza Saleh et al.   HYPERTENSION

Hypertension and VEGF (Vascular Endothelial Growth Factor) Receptor Tyrosine Kinase InhibitionNovelty and Significance

(2017) Brian C. Boursiquot et al.   HYPERTENSION

Salt Sensitivity of Angiogenesis Inhibition–Induced Blood Pressure RiseNovelty and Significance

(2017) Stephanie Lankhorst et al.   HYPERTENSION

Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition

(2017) Rhian M. Touyz et al.   HYPERTENSION

Inflammatory role of high salt level in tumor microenvironment (Review)

(2017) Suneetha Amara et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis

(2017) Giandomenico Roviello et al.   INVESTIGATIONAL NEW DRUGS

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial

(2017) Maria E. Cabanillas et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

(2017) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia

(2017) Daniel L. Rolnik et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas

(2017) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Renal cell carcinoma

(2017) James J. Hsieh et al.   Nature Reviews Disease Primers

Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data

(2016) Michael J Sorich et al.   BRITISH JOURNAL OF CANCER

VEGFB/VEGFR1-Induced Expansion of Adipose Vasculature Counteracts Obesity and Related Metabolic Complications

(2016) Marius R. Robciuc et al.   Cell Metabolism

Association of Plasminuria with Overhydration in Patients with CKD

(2016) A. Schork et al.   Clinical Journal of the American Society of Nephrology

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

(2016) Jose Luis Zamorano et al.   EUROPEAN HEART JOURNAL

Mechanisms of Hypertension and Renal Injury During Vascular Endothelial Growth Factor Signaling Inhibition

(2016) Anton H. van den Meiracker et al.   HYPERTENSION

Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials

(2016) Michael J. Sorich et al.   INTERNATIONAL JOURNAL OF CANCER

Oxidative stress inactivates VEGF survival signaling in retinal endothelial cells via PI 3-kinase tyrosine nitration

(2016) Azza B. El-Remessy et al.   JOURNAL OF CELL SCIENCE

Sildenafil Prevents Podocyte InjuryviaPPAR-γ–Mediated TRPC6 Inhibition

(2016) Ramon Sonneveld et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Ten years of anti-vascular endothelial growth factor therapy

(2016) Napoleone Ferrara et al.   NATURE REVIEWS DRUG DISCOVERY

Cardiovascular Toxic Effects of Targeted Cancer Therapies

(2016) Javid J. Moslehi   NEW ENGLAND JOURNAL OF MEDICINE

Redox mechanisms in pathological angiogenesis in the retina: roles for NADPH oxidase

(2015) Elsa Chan et al.   CURRENT PHARMACEUTICAL DESIGN

Greater Sensitivity of Blood Pressure Than Renal Toxicity to Tyrosine Kinase Receptor Inhibition With SunitinibNovelty and Significance

(2015) Stephanie Lankhorst et al.   HYPERTENSION

Association Studies Suggest a Key Role for Endothelin-1 in the Pathogenesis of Preeclampsia and the Accompanying Renin–Angiotensin–Aldosterone System SuppressionNovelty and Significance

(2015) Koen Verdonk et al.   HYPERTENSION

Neuropilin Functions as an Essential Cell Surface Receptor

(2015) Hou-Fu Guo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib

(2015) Stephanie Lankhorst et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

(2015) Martin Schlumberger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs

(2015) Isabel Ben-Batalla et al.   Oncotarget

Microalbuminuria is a predictor of adverse pregnancy outcomes including preeclampsia

(2015) M. Jayaballa et al.   Pregnancy Hypertension-An International Journal of Womens Cardiovascular Health

Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors

(2015) L. León-Mateos et al.   Redox Biology

Hypertension Due to Antiangiogenic Cancer Therapy With Vascular Endothelial Growth Factor Inhibitors: Understanding and Managing a New Syndrome

(2014) Heather Yvonne Small et al.   CANADIAN JOURNAL OF CARDIOLOGY

Risk of Hypertension in Cancer Patients Treated with Aflibercept: A Systematic Review and Meta-Analysis

(2014) Wei-Xiang Qi et al.   CLINICAL DRUG INVESTIGATION

Early Rise in Aldosteron is Correlated with Increase in Blood Pressure in Sunitinib Treated Patients with Metastatic Renal Cell Carcinoma

(2014) A. Thijs et al.   CLINICAL THERAPEUTICS

Ponatinib: A Review of Its Use in Adults with Chronic Myeloid Leukaemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia

(2014) Sheridan M. Hoy   DRUGS

Treatment of Hypertension and Renal Injury Induced by the Angiogenesis Inhibitor Sunitinib

(2014) Stephanie Lankhorst et al.   HYPERTENSION

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

(2014) Marcia S Brose et al.   LANCET

Determining the optimal dose in the development of anticancer agents

(2014) Ron H. J. Mathijssen et al.   Nature Reviews Clinical Oncology

Urinary serine proteases and activation of ENaC in kidney—implications for physiological renal salt handling and hypertensive disorders with albuminuria

(2014) Per Svenningsen et al.   PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY

SFlt-1 Elevates Blood Pressure by Augmenting Endothelin-1-Mediated Vasoconstriction in Mice

(2014) Fouad Amraoui et al.   PLoS One

Vascular Endothelial Growth Factor Inhibitor-Induced Hypertension: From Pathophysiology to Prevention and Treatment Based on Long-Acting Nitric Oxide Donors

(2013) P. Kruzliak et al.   AMERICAN JOURNAL OF HYPERTENSION

Reactive Oxygen Species, Vascular Noxs, and Hypertension: Focus on Translational and Clinical Research

(2013) Augusto C. Montezano et al.   ANTIOXIDANTS & REDOX SIGNALING

Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis

(2013) Wei-Xiang Qi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis

(2013) Zexing Wang et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

VEGF-A induces its negative regulator, soluble form of VEGFR-1, by modulating its alternative splicing

(2013) Tetsuya Saito et al.   FEBS LETTERS

Role of Endogenous Vascular Endothelial Growth Factor in Endothelium-Dependent Vasodilation in Humans

(2013) Anna M.J. Thijs et al.   HYPERTENSION

Vascular Endothelial Growth Factor-A and Aldosterone

(2013) Carine Gennari-Moser et al.   HYPERTENSION

Cabozantinib in Progressive Medullary Thyroid Cancer

(2013) Rossella Elisei et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis

(2013) T Funakoshi et al.   JOURNAL OF HUMAN HYPERTENSION

Comprehensive molecular characterization of clear cell renal cell carcinoma

(2013)   NATURE

Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives

(2013) Steven M. Bair et al.   TRENDS IN CARDIOVASCULAR MEDICINE

Antioxidant properties of glutamine and its role in VEGF-Akt pathways in portal hypertension gastropathy

(2013) Camila Marques   WORLD JOURNAL OF GASTROENTEROLOGY

Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension

(2012) Peter Kruzliak et al.   ANGIOGENESIS

Vascular endothelin receptor type B: Structure, function and dysregulation in vascular disease

(2012) Marc Q. Mazzuca et al.   BIOCHEMICAL PHARMACOLOGY

Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials

(2012) Wei-Xiang Qi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Nrf-2 overexpression in mesenchymal stem cells reduces oxidative stress-induced apoptosis and cytotoxicity

(2012) Mohammad Mohammadzadeh et al.   CELL STRESS & CHAPERONES

Nox4 Is a Protective Reactive Oxygen Species Generating Vascular NADPH Oxidase

(2012) Katrin Schröder et al.   CIRCULATION RESEARCH

Urinary Plasmin Activates Collecting Duct ENaC Current in Preeclampsia

(2012) Kristian B. Buhl et al.   HYPERTENSION

Management of Antiangiogenic Therapy-Induced Hypertension

(2012) Nilka de Jesus-Gonzalez et al.   HYPERTENSION

Mechanism of hypertension and proteinuria during angiogenesis inhibition

(2012) Stephanie Lankhorst et al.   JOURNAL OF HYPERTENSION

Renoprotective Effects of Sildenafil in DOCA-Salt Hypertensive Rats

(2012) Eun Hui Bae et al.   KIDNEY & BLOOD PRESSURE RESEARCH

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials

(2012) Peter M Rothwell et al.   LANCET

Cardiac angiogenic imbalance leads to peripartum cardiomyopathy

(2012) Ian S. Patten et al.   NATURE

Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition

(2012) S. B. Sunshine et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Contrary Effects of the Receptor Tyrosine Kinase Inhibitor Vandetanib on Constitutive and Flow-Stimulated Nitric Oxide Elaboration in Humans

(2011) Erica L. Mayer et al.   HYPERTENSION

The Vascular Endothelial Growth Factor Receptor Inhibitor Sunitinib Causes a Preeclampsia-Like Syndrome With Activation of the Endothelin System

(2011) Mariëtte H.W. Kappers et al.   HYPERTENSION

Sunitinib-Induced Systemic Vasoconstriction in Swine Is Endothelin Mediated and Does Not Involve Nitric Oxide or Oxidative Stress

(2011) Mariëtte H.W. Kappers et al.   HYPERTENSION

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer

(2011) M. Manzoni et al.   ONCOLOGY

Regulation of Blood Pressure and Salt Homeostasis by Endothelin

(2011) Donald E. Kohan et al.   PHYSIOLOGICAL REVIEWS

Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis

(2010) V. Ranpura et al.   AMERICAN JOURNAL OF HYPERTENSION

Increased renal α-epithelial sodium channel (ENAC) protein and increased ENAC activity in normal pregnancy

(2010) Crystal West et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats

(2010) Yoshihiro Kuno et al.   BRITISH JOURNAL OF PHARMACOLOGY

HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors

(2010) F. Shojaei et al.   CANCER RESEARCH

Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: Potential markers for aggressive phenotypes

(2010) A. Salajegheh et al.   EJSO

Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor–Signaling Inhibitors

(2010) Emily S. Robinson et al.   HYPERTENSION

Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels

(2010) Mariëtte H.W. Kappers et al.   HYPERTENSION

Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors

(2010) Michael L. Maitland et al.   JNCI-Journal of the National Cancer Institute

Serum Vascular Endothelial Growth Factor C Correlates With Lymph Node Metastases and High-Risk Tumor Profiles in Papillary Thyroid Carcinoma

(2009) Xiao-Min Yu et al.   ANNALS OF SURGERY

Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment

(2009) M. L. Maitland et al.   CLINICAL CANCER RESEARCH

Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression

(2009) Carie S. Facemire et al.   HYPERTENSION

ETA Receptor Blockade With Atrasentan Prevents Hypertension With the Multitargeted Tyrosine Kinase Inhibitor ABT-869 in Telemetry-instrumented Rats

(2009) Patricia N Banfor et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C–dependent buffering mechanism

(2009) Agnes Machnik et al.   NATURE MEDICINE

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis

(2008) Xiaolei Zhu et al.   ACTA ONCOLOGICA

Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor

(2008) N. Steeghs et al.   CLINICAL CANCER RESEARCH

Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy

(2008) J. O. Curwen et al.   CLINICAL CANCER RESEARCH

Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

(2008) J. H. Finke et al.   CLINICAL CANCER RESEARCH

Home Blood-Pressure Monitoring in Patients Receiving Sunitinib

(2008) Michel Azizi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE